Blog
RSS FeedPosted by Michael Wonder on 30 May 2019
Janssen announces Health Canada approval of Tremfya One-Press (guselkumab) - a patient-controlled injector for adults with moderate-to-severe plaque psoriasis
29 May 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved Tremfya One-Press, ...
Posted by Michael Wonder on 23 May 2019
B.C. eye doctors warn province of spike in glaucoma cases linked to injections of eye drug
23 May 2019 - Thousands of retinal-disease patients in British Columbia are being exposed to an “increased risk of severe ...
Posted by Michael Wonder on 23 May 2019
Health Canada approves Mylan and Biocon's Ogivri, the first trastuzumab biosimilar, for the treatment of HER2-positive breast and gastric cancers
22 May 2019 - Ogivri is a part of Mylan's robust portfolio of 20 biosimilar and insulin analog products. ...
Posted by Michael Wonder on 21 May 2019
New made-in-Canada technique could revolutionise vaccine transportation
21 May 2019 - Researchers in Ontario have developed a new method of transporting life-saving vaccines to remote and impoverished ...
Posted by Michael Wonder on 17 May 2019
Health Canada approves injectable hydromorphone to treat opioid addiction
16 May 2019 - Canada is first country to approve the pain drug for severe opioid use disorder, says Health ...
Posted by Michael Wonder on 14 May 2019
Helping Canadians get faster access to the prescription drugs they need to live healthier lives
13 May 2019 - Government of Canada consults on new approach to fast-track the review of treatments for serious, rare ...
Posted by Michael Wonder on 09 May 2019
First and only PARP inhibitor, Lynparza (olaparib) approved as a first-line maintenance therapy treatment in BRCA mutated advanced ovarian cancer
8 May 2019 - AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to ...
Posted by Michael Wonder on 04 May 2019
Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada
3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma ...
Posted by Michael Wonder on 03 May 2019
Cresemba now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis
2 May 2019 - AVIR Pharma is pleased to announce that Cresemba (isavuconazole, as isavuconazonium sulphate), an anti-fungal approved for the ...
Posted by Michael Wonder on 30 Apr 2019
New drug submission filed for Vascepa with Health Canada
29 April 2019 - Amarin Corporation today announced that its licensee in Canada, HLS Therapeutics has filed a new drug ...
Posted by Michael Wonder on 20 Apr 2019
Health Canada approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis
18 April 2019 - Approval of Skyrizi (risankizumab) is based on results from clinical studies showing significant improvement in levels of ...
Posted by Michael Wonder on 17 Apr 2019
Increasing access to new treatments for special patient populations
16 April 2019 - Health Canada is helping Canadians get timely access to new drugs. ...
Posted by Michael Wonder on 16 Apr 2019
Recordati to seek Canadian approval for kidney disease drug
17 April 2019 - Italy’s Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which ...
Posted by Michael Wonder on 12 Apr 2019
Health Canada issues Notice of Compliance with Conditions for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinom
11 April 2019 - Cutaneous squamous cell carcinoma is the second most common skin cancer in Canada. ...
Posted by Michael Wonder on 11 Apr 2019
Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan in Canada for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis
10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance for Truxima (rituximab), the ...